Tracy Frech is a Rheumatology/Immunology physician affiliated with Vanderbilt University. OpenAlex indexes 290 publications with 7,708 citations (h-index 42); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
719 Thompson Ln
Nashville, TN 372043609
Telephone
615-322-3000Provider last certified this registry record 25 Jul 2025.
Clinical trials
- Systemic Sclerosis (SSc) Vasculopathy: Improved Clinical Monitoring and Treatment
Sponsor: VA Office of Research and Development
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Antiparasitic
33.4%Antimalarial33.4%Hydroxychloroquine Sulfate100%Part D≥29 patientsCardiovascular
29.4%Calcium channel blocker25.6%Amlodipine Besylate100%Part D≥27 patientsAngiotensin receptor blocker (ARB)3.8%Losartan Potassium100%Part D<11 patientsMetabolism & gastrointestinal
16.7%Proton pump inhibitor7.2%Omeprazole100%Part D<11 patientsH2 blocker5.5%Famotidine100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
3 NIH research awards on record, funded 2021–2026 per NIH RePORTER. The latest:
- Predicting risk of systemic autoimmune disease in patients with positive antinuclear antibodies
Vanderbilt University Medical Center
FY2026$393,139R01AR080629 - Predicting risk of systemic autoimmune disease in patients with positive antinuclear antibodies
Vanderbilt University Medical Center
FY2025$401,415R01AR080629
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
William Schaffner, MD
Vanderbilt University
Keith Obstein, MD, MPH
Vanderbilt University
Andrew Jallouk, MD, PhD
Vanderbilt University
Salim Yusuf
Vanderbilt University
David Felson, MD
Boston University
Marc Hochberg, MD
University of Maryland School of Medicine
Philip Mease, MD
Michelle Petri, MD
Johns Hopkins University School of Medicine
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”